EQS-News: CompuGroup Medical SE & Co. KGaA
/ Key word(s): Investment
Koblenz: CompuGroup Medical SE & Co. KGaA (CGM), a worldwide leading e-health company, acquires a 20 percent stake in the Italian-based New Line RdM Società Benefit S.p.A. (New Line), thereby strengthening its position in the Italian healthcare data market. The investment represents the first step of entering international markets for innovative data solutions. Founded in 1981, New Line provides customer-specific pharmacy consumption market analyses for major drug distributors, cooperatives, chains of pharmacies, parapharmacies and e-commerce companies. An experienced player in the analysis of pharmacy market data, New Line has expanded its panel of pharmacies in recent years to currently more than 12,000. This has led to a significantly increased customer base, both among pharmaceutical companies and among consumer health and personal care companies. Having partnered with New Line for several years, CGM is expanding its exposure to data-driven solutions on an international scale. This transaction is another proof point underpinning CGM’s ambition to become a leading European health data service provider, following the acquisition of INSIGHT Health in May 2022. Gabriele Pierani, President and CEO of New Line, states: “CGM becoming a shareholder of New Line is testimony to the potential of our innovative data-based solutions. This partnership will allow us to continue our strong growth, with the entry into new markets, both in Italy and in Europe. We are looking forward to collaborating with INSIGHT Health and CGM to provide added value for our multinational customers.” Eckart Pech, Managing Director Consumer and Health Management Information Systems in CGM, notes: "We are taking the next step in expanding our strategic position in data-based solutions for healthcare. Our investment in New Line gives us access to the pharmaceutical market in Italy, enabling a more comprehensive coverage of the European healthcare market.”
About CompuGroup Medical SE & Co. KGaA CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 1.025 billion in 2021, its software products are designed to support all medical and organizational activities in doctors’ offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the health care system and its web-based personal health records contribute towards safer and more efficient health care. CompuGroup Medical’s services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists, and other health care professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the e-health company with one of the highest coverages among health care professionals. More than 8,500 highly qualified employees support customers with innovative solutions for the steadily growing demands of the health care system.
14.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | CompuGroup Medical SE & Co. KGaA |
Maria Trost 21 | |
56070 Koblenz | |
Germany | |
Phone: | +49 (0)160 3630362 |
Fax: | +49 (0)261 8000 3200 |
E-mail: | investor@cgm.com |
Internet: | www.cgm.com |
ISIN: | DE000A288904 |
WKN: | A28890 |
Indices: | SDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1512843 |
End of News | EQS News Service |
|
1512843 14.12.2022 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.